In vivo CAR-T/M generates CAR-T or CAR-M cells inside the body via targeted delivery of CAR-encoding mRNA, removing ex vivo cell collection, culture and reinfusion. Baiti Biotech provides technology development and collaborative research services in this area.
| 技术原理 | 靶向 LNP 递送 CAR mRNA → 体内免疫细胞原位表达 CAR |
|---|---|
| 与体外 CAR-T 的差异 | 无需白细胞单采、体外扩增、清淋预处理与回输 |
| 研究方向 | 肿瘤、纤维化与自身免疫等难治性复发型疾病 |
| 服务形式 | 技术开发、机制研究与合作研究 |
依托自研 tpLNP 靶向递送平台与 LINCMECAR® 体内 CAR-T/M 技术体系;相关研究以公开专利与国际临床注册(ClinicalTrials.gov,如 NCT07523555、NCT07523542)为可核验依据。
Sources: Baiti Biotech official site (www.100biotech.com), patent publications and ClinicalTrials.gov registrations. Updated 2026-11-21.
Baiti Biotech is an AI for Science medical research technology service company. It provides research technology services and collaborative research, not clinical treatment for patients.